US Food and Drug Administration (USFDA) has successfully concluded inspection at Indoco Remedies’ Clinical Research Organisation, AnaCipher with zero 483s. The inspection was held from October 14, 2019 to October 18, 2019. The CRO - AnaCipher conducts Bio-Equivalence and Bio-Availability (BA/BE) studies at its facility in Hyderabad and is spread over an area of 30,000 sq. ft. with 98 beds.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.